PSMA therapy with Lutetium-177 (Lu-177)

Lutetium-177 PSMA therapy is the latest, personalized medical procedure that involves administering the radioactive isotope Lu-177 into the patient’s body for targeted destruction of tumor tissues in prostate cancer.

The radiation dose affecting other parts of the body is minimal, and a portion of Lu-177 is excreted through saliva, urine, and feces. As a result, this therapy is considered relatively safe, with a low risk of systemic side effects.

Lu-177 therapy is also used in patients with third and fourth stage prostate cancer to reduce toxic burden. The biochemical effectiveness of this therapy is determined by a PSA reduction of more than 50% in blood tests.

Features of the procedure in global clinics

In European countries, strict legislative oversight ensures high-quality and safe treatment for both local and international patients.

A major advantage of Lu-177 PSMA therapy is the single administration of the radionuclide on the day of hospitalization. Depending on the stage of the tumor, an oncologist prescribes a specific number of treatment cycles.